HOMEVULNERABILITIESCVE-2025-57543
MEDIUM

CVE-2025-57543

Published: March 16, 2026· Updated: Mar 20, 2026

6.1
CVSS v3.1
EPSS:0.03%probability of exploitation in 30 daysPercentile:7.9th

Official Description

Cross Site scripting vulnerability (XSS) in NetBox 4.3.5 "comment" field on object forms. An attacker can inject arbitrary HTML, which will be rendered in the web UI when viewed by other users. This could potentially lead to user interface redress attacks or be escalated to XSS in certain contexts.

NVD Source

Technical Analysis

CVE-2025-57543 can be exploited remotely over the network without requiring physical or adjacent access, significantly expanding the attack surface for threat actors.

Exploitation does not require any privileges, though user interaction (Required) is needed, which slightly reduces the risk of mass automated attacks.

The vulnerability has a "Changed" scope, meaning successful exploitation can impact components beyond the vulnerable component itself — such as the host operating system or adjacent services.

CVSS v3.1 Vector Breakdown

Exploitability
Attack VectorNetwork
Attack ComplexityLow
Privileges Req.None
User InteractionRequired
ScopeChanged
Impact
ConfidentialityLow
IntegrityLow
AvailabilityNone
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:L/A:N

Affected Vendors & Products

netbox1 product
netbox
Source: NVD CPE · 1 total CPE entries

Exploit & PoC Resources

NO KNOWN EXPLOITNo public exploit confirmed at this time
External links open in a new tab. Always verify in a controlled environment before use.

Official Patches & Advisories

All References (2)

Quick Facts

CVE IDCVE-2025-57543
CVSS Score6.1 / 10
SeverityMEDIUM
CISA KEVNo
EPSS (30d)0.03%
Affected1 vendor
PublishedMar 16, 2026

Recommended Actions

  • Apply vendor patches immediately
  • Monitor CVE-2025-57543 in threat intel feeds
  • Review IDS/IPS signatures for exploitation attempts
Data sourced from NVD (NIST), CISA KEV, and EPSS (FIRST). Analysis generated by CTIWATCH.COM. CVE data is provided under the NVD usage policy.